This page is updated frequently with new G Protein-related patent applications.
| Method for using protein databases to identify microorganisms|
A method for identifying microorganisms by maldi-tof mass spectrometry includes acquiring a maldi mass spectrum of a microorganism, detecting peaks in the acquired maldi spectrum, generating a peak list comprising mass and intensity from the detected peaks in the acquired maldi spectrum, acquiring a database of protein sequences deduced from dna sequences for microorganisms, generating a sub-database of ribosomal proteins from the protein sequences and their masses in the database, matching masses of the detected peaks in the acquired maldi spectrum to masses of the ribosomal proteins in the generated sub-database, scoring the matches obtained above for each represented microorganism, generating a peak list of accurate masses of matched ribosomal proteins, recalibrating the peak list comprising mass and intensity with the peak list of accurate masses of matched ribosomal proteins, identifying a microorganism with the highest score, and repeating until a desired improvement in the recalibrated peak list or a validated identification is achieved.. .
Virgin Instruments Corporation
| Isolation of polymerase-nucleic acid complexes|
Compositions, methods and systems are provided for isolating dna having a modified or unnatural base. Circular dna fragments, each comprising a double stranded dna central region and single stranded regions on the ends of the double stranded regions, are obtained.
Pacific Biosciences Of California, Inc.
| Method for attaching one or more polynucleotide binding proteins to a target polynucleotide|
The invention relates to new methods of attaching one or more polynucleotide binding proteins to a target polynucleotide. The invention also relates to new methods of characterising target polynucleotides..
Oxford Nanopore Technologies Ltd.
| Bardcoded protein array for multiplex single-molecule interaction profiling|
Methods for attaching barcodes to polypeptides are provided. Methods for detecting molecular interactions at the single molecule level are provided.
President And Fellows Of Harvard College
| A directing proteins to specific loci in the genome and uses thereof|
Disclosed are compositions and methods for directing proteins to specific loci in the genome and uses thereof. In one aspect, the disclosed methods allow for directing proteins to specific loci in the genome of an organism, including the steps of providing a dna localization component and an effector molecule, wherein the dna localization component and the effector molecule are capable of being operatively linked via a non-covalent linkage..
Poseida Therapeutics, Inc.
| Rhamnose promoter expression system|
The prokaryotic signal sequence is selected from signal peptides of periplasmatic binding proteins for sugars, amino acids, vitamins and ions. The expression of the nucleic acid sequence is controlled by the promoter region.
| Human lambda light chain mice|
Genetically modified mice are provided that express human λ variable (hvλ) sequences, including mice that express hvλ sequences from an endogenous mouse λ light chain locus, mice that express hvλ sequences from an endogenous mouse κ light chain locus, and mice that express hvλ sequences from a transgene or an episome wherein the hvλ sequence is linked to a mouse constant sequence. Mice are provided that are a source of somatically mutated human λ variable sequences useful for making antigen-binding proteins.
Regeneron Pharmaceuticals, Inc.
| Dual receptor antagonistic antigen-binding proteins and uses thereof|
This disclosure relates to antagonistic dual receptor antigen-binding proteins, e.g. Antibodies and methods of using the dual receptor antibodies for treatment of pathological diseases.
| Specific sorbent for binding proteins and peptides, and separation method using the same|
Sorbent comprising a solid support material, the surface of which comprises first residues comprising a binuclear heteroaromatic structure comprising besides carbon atoms at least one of the heteroatoms n, o, s, and second residues comprising a mononuclear heteroaromatic structure comprising besides carbon atoms at least one of the heteroatoms n, o, s.. .
| Delivery of therapeutic agents by a collagen binding protein|
Methods of delivering therapeutic agents by administering compositions including a bacterial collagen-binding polypeptide segment linked to the therapeutic agent to subjects in need of treatment with the therapeutic agent are provided. Methods of treating hyperparathyroidism, and hair loss using compositions comprising a collagen binding polypeptide and a pth/pthrp receptor agonist are provided.
Montefiore Medical Center
Enteral formulations for preterm infants comprising optimised phenylalanine intake levels
The present invention relates to enteral formulations for preterm infants (e.g., preterm formulas and human milk fortifiers) containing optimised intake levels of phenylalanine for the preterm infants. It particularly relates to a preterm formulation comprising a proteinaceous composition, wherein the preterm formulation (a) comprises 2.0-2.29 g phenylalanine per 100 g protein; (b) comprises 64.00-82.29 mg phenylalanine per 100 kcal; and/or (c) provides, or is formulated to provide phenylalanine in an amount of 80-96 mg/kg body weight per day..
Activity of fe-s cluster requiring proteins
The present invention is related to a recombinant host cell, in particular a yeast cell, comprising a dihydroxy-acid dehydratase polypeptide. The invention is also related to a recombinant host cell having increased specific activity of the dihydroxy-acid dehydratase polypeptide as a result of increased expression of the polypeptide, modulation of the fe—s cluster biosynthesis of the cell, or a combination thereof.
Butamax Advanced Biofuels Llc
Modulation of gene expression and screening for deregulated protein expression
Disclosed herein include compositions and methods of modulating protein expression that utilizes an activator or a repressor of a non-sense mediated rna decay switch exon (nse). In some embodiments, also included herein are compositions and methods of modulating protein expression that uses an agent that targets a transposed element..
University Of Southampton
Protein adhesion inhibitor
To provide an inhibitor for inhibiting protein adhesion capable of easily forming a coating layer which is excellent in water resistance, from which coating components are less likely to be eluted, on which protein is less likely to be adsorbed and which is excellent in biocompatibility; a coating solution; a medical device having a coating layer employing this inhibitor for inhibiting protein adhesion; a method for producing the same; and a fluoropolymer to be used in this inhibitor for inhibiting protein adhesion. A compound for inhibiting protein adhesion comprising a fluoropolymer that has units having a biocompatible group, a fluorine atom content of from 5 to 60 mass % and a proportion p represented by the following formula of from 0.1 to 4.5%.
Asahi Glass Company, Limited
Antigen-binding proteins that activate the leptin receptor
The present invention provides antibodies and antigen-binding fragments of antibodies that bind to leptin receptor (lepr), and methods of using the same. According to certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind lepr and activate lepr signaling.
Regeneron Pharmaceuticals, Inc.
Methods and reagents for analyzing protein-protein interfaces
The present disclosure provides methods and reagents useful for analyzing protein-protein interfaces such as interfaces between a presenter protein (e.g., a member of the fkbp family, a member of the cyclophilin family, or pin1) and a target protein. In some embodiments, the target and/or presenter proteins are intracellular proteins.
Warp Drive Bio, Inc.
Hybrid suppressor trna for vertebrate cells
This invention provides compositions and methods for producing translational components that expand the number of genetically encoded amino acids in vertebrate cells. The components include orthogonal trna's, orthogonal aminoacyl-trna synthetases, orthogonal pairs of trna's/synthetases and unnatural amino acids.
Dual specific binding proteins having a receptor sequence
Engineered multispecific binding proteins that bind at least one ligand for a receptor are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.. .
Peptide tags for labeling proteins by fusion, and antibodies for the detection thereof
Peptide tags (tags) are provided for their fusion to proteins at the n-terminal or c-terminal ends, which are defined by a series of structural and functional properties that define their safety with regard to the modification of the structure or biological function of the protein or peptide to which they are fused, and wherein the tag-protein is selected from a group consisting of a fragment of phl p 2 pheleum pratense , a fragment of hev b 6.02 hevea brasiliensis, and a fragment of amb t 5 ambrosia trifida, or a combination thereof. Methods are also provided for the production and detection of these recombinant fusion proteins as well as specific antibodies that bind to these tags..
Instituto De BiologÍa Molecular De Barcelona- Consejo Superior De Investigaciones Cientificas
Methods for making conjugates from disulfide-containing proteins
The invention provides methods to prepare protein conjugates from proteins having at least four accessible cysteine residues. In one embodiment, an antibody with four reducible disulfide linkages is reduced to provide four pairs of free cysteines.
N-acetylglucosamine sugar chain group-containing compound, carrier compound for drug delivery, drug preparation, and drug delivery system
An n-acetylglucosamine sugar chain group-containing compound which can easily reach cells/sites on which a vimentin and/or desmin protein(s) is/are exposed, which compound has excellent affinity to n-acetylglucosamine sugar chain-recognizing proteins; a drug delivery carrier compound comprising the compound: a preparation using the drug delivery earner compound; and a drug delivery system; are provided. These are an n-acetylglucosamine sugar chain group-containing compound having a weight average molecular weight within the range of 15,000 to 100,000; a drug delivery carrier compound comprising the compound; a preparation using the drug delivery carrier compound; and a drug delivery system..
The present invention relates to pharmaceutical formulations of a pharmaceutically active antigen binding protein, for example a monoclonal antibody. Such formulations comprise, in addition to the antigen binding protein, a buffering agent and a tonicity agent..
Glaxosmithkline Intellectual Property Management Limited
Methods for modulating cancer cells and stem cells
The present invention provides methods for modulating pluripotency of stem cells and proliferation of cancer cells. The modulation is achieved by promoting dephosphorylation of mrna-binding protein 3 (rbm3) and down-regulating expression or cellular level of pluripotency factor lin28.
The Scripps Research Institute
Methods and compositions for wound treatment
The present disclosure relates to methods for identifying proteins or peptide motifs of intracellular, extracellular, or extracellular matrix proteins specifically exposed in wound sites, as well as compositions for treating wounds, and methods for their use.. .
T cell receptor-like antibodies specific for a wti peptide presented by hla-a2
The present invention provides antigen binding proteins that specifically bind to wilms' tumor protein (wt1), including humanized, chimeric and fully human antibodies against wt1, antibody fragments, chimeric antigen receptors (cars), fusion proteins, and conjugates thereof. The antigen binding proteins and antibodies bind to hla-a0201-restricted wt1 peptide.
Eureka Therapeutics, Inc.
Hybridoma cell lines (my-c-cc0c2-235-3h8) and use thereof for producing a monoclonal antibody against the human cardiac myosin binding protein c (c-protein, mybpc3, cmybp-c or my-c)
Monoclonal antibodies, which can be produced in vitro, against cardiac epitopes of the human my-c are produced by generating myeloma cell clones that produce such specific antibodies having epitope specificity. These monoclonal antibodies allow, among other things, the creation of an enzyme-linked immunosorbent assay (elisa) for the specific, cross-reactivity-free quantitative determination of my-c in serum, plasma, whole blood or other body fluid.
Antigen binding proteins that interact with asgr, asgr-1 and/or asgr-2 are described as well as methods of making and using such antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of asgr, asgr-1 and/or asgr-2 antigen binding proteins.
Pd-1 binding proteins and methods of use thereof
Provided herein are compositions, methods and uses involving antibodies that specifically bind to programmed death-1 (pd-1) and modulate the expression and/or activity of pd-1.. .
Single-chain multivalent binding protein compositions and methods
Provided are protein, nucleic acid, and cellular libraries of single chain multivalent binding proteins (e.g., scdvd and scdvdfab molecules) and methods of using these of these libraries for the screening of single chain multivalent binding proteins using cell surface display technology (e.g., yeast display).. .
Substituted indol-5-ol derivatives and their therapeutical applications
The present invention relates generally to the use of compounds to treat a variety of disorders, diseases and pathologic conditions and more specifically to the use of substituted indol-5-ol derivatives to modulate protein kinases and for treating protein kinase-mediated diseases.. .